Session 1: Current efficacy trial design approaches – challenges and lessons learned
Help us frame the live conversation on 27 October 2020 by watching these bite-size talks and submitting your questions and comments ahead of time using the link under each presentation. You can also email us at Enterprise@Iasociety.org and, of course, get in touch if you need help navigating the event.
Prep considerations for the MOSAICO trial (S1-03), Susan Buchbinder, MD, University of California San Francisco, USA
Community-informed efforts towards the MOSAICO study (S1-04), Stephaun Wallace, PhD, MS, Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA
HPTN 083: Where did we go right? (S1-05), Raphael Landovitz, MD, University of California, USA
Contingency plans: modelling effectiveness using counterfactuals (S1-06), Deborah Donnell, PhD, Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA
PrEPVacc concepts – registrational cohort and prequalification period (S1-07), Eugene Ruzagira, MBChB, MPH, PhD, MRC/UVRI Uganda Research Unit, Entebbe, Uganda
Pre-randomization incidence can approximate a control group, David Glidden, PhD, University of California San Francisco, San Francisco, USA